Aerocrine enters into a license agreement with Medisoft

SOLNA, Sweden –March 25, 2013 – Aerocrine AB today announced the signing of a license agreement with Medisoft S.A. The agreement includes the withdrawal of all patent proceedings between the companies.

Medisoft has entered into a license agreement with Aerocrine under Aerocrine’s European Patents EP 0 606 351, EP 0724 723, EP 1439 781, EP 1661 514, EP 1 545 305, EP 0 973 444 and EP 0 892 926 and their respective Indian and Australian counterparts. The royalty bearing license grants Medisoft the right to manufacture its current HypAir FeNO, HypAir FeNO+ and HypAir NO Nasal products in Belgium and to sell the products in Europe, Australia and India under Aerocrine’s patents.

The parties have agreed to settle all ongoing litigation in Germany and Belgium as part of the license agreement. Aerocrine will discontinue the pending patent infringement proceedings, and Medisoft will withdraw the pending nullity suits in respect of the EP 0 606 351, EP 0724 723, EP 1439 781 and EP 1661 514. Consequently, where there has been a challenge to the validity Aerocrine’s patents in Germany and Belgium, the patents will be reinstated as valid in the form they were originally granted.

“I commend Medisoft for their competitive spirit. Both companies can now focus on the marketing of their products instead of consuming resources in the various courts”, commented Aerocrine CEO Scott Myers.

For more information, contact:

Scott Myers, CEO, Aerocrine AB: +46 768 788 379 or +1 970 368 0336

Mats Carlson, Chief Technology Officer, Aerocrine AB: +46 8 629 07 83

About Aerocrine

Aerocrine AB is a medical technology company focused on the improved management and care of patients with inflammatory airway diseases such as Asthma. Within this sector, Aerocrine is the world leader. Aerocrine markets NIOX MINO®, which enables fast and reliable point of care measurement of airway inflammation. This product plays a critical role in more effective diagnosis, treatment and follow-up of patients affected with inflammatory airway diseases. Aerocrine is based in Sweden with subsidiaries in the U.S., Germany, Switzerland and the U.K. Aerocrine shares have been listed on the Stockholm Stock Exchange since 2007 (AERO-B.ST). For more information please visit www.aerocrine.com and www.niox.com.

Aerocrine may be required to disclose the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 8:00 a.m. on March 25, 2013.

About Us

Aerocrine AB is a medical technology company focused on the improved management and care of patients with inflammatory airway diseases. As the pioneer and leader in the technology to monitor and manage airway inflammation, Aerocrine markets NIOX® Flex and NIOX MINO®. Both products enable fast and reliable management of airway inflammation and may therefore play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries in the US, Germany and the UK. Aerocrine shares were listed on the Stockholm Stock Exchange on 15 June 2007.

Subscribe

Documents & Links